ALSO NOTED: Wyeth plant sold to Akrimax; Schering suit settled in lawyers' favor;

> Wyeth Pharmaceutical sold its Rouses Point, NY, plant to Akrimax Pharmaceutical, which intends to continue operating the facility and retain most of its 900 employees. Report

> Shareholders sued Schering-Plough, but only their lawyers got paid. The drug makers have to hand over $9.5 million to plaintiffs counsel and pledge to reform its governance. Report

> Stryker, which makes artificial knees and hips, got an FDA warning letter stemming from quality problems at its Mahwah, N.J., plant. Report

> India's Natco Pharma has applied for a compulsory license on Roche's lung cancer med Tarceva, which it intends to copy and export to Nepal. Report

> Shire announced its intent to expand in Latin America; the company recently added Mexico City operations to its portfolio in South America. Release

> OncoMed's $1.4 billion antibody development pact with GlaxoSmithKline has put a premium on preclinical programs. Report

> A number of top European pharmaceutical companies and CRS are bringing a close to an 80-year era of animal tests for acute toxicity. Report

> Don't look to Europe for many new chemical entity approvals in '08, analysts say. Report 

And Finally... Could asthma and allergy prevention start in the womb, rather than with once-a-day meds? Report

Suggested Articles

Horizon Therapeutics has notched an FDA approval for its rare eye disease med Tepezza (teprotumumab), a possible blockbuster drug in the making.

Eli Lilly has a pipeline stuffed with a host of assets and has decided it needs a new injectable drug and device plant to manufacture some of them.

After Clovis’ Rubraca snagged an FDA boost in prostate cancer last week, AZ and Merck’s rival Lynparza has matched it with a boost of its own.